“…Whereas the CTD mutants L386A, L397A, and L466A had only a minor effect on SHARP binding (Table 3), consistent with these residues burying much less surface area at the CTD-SHARP interface (L386=39 Å 2 , L397=3 Å 2 , and L466=44 Å 2 ). Because SHARP binds the BTD of RBPJ in a structurally similar manner to the RAM domain of NICD, and the corepressors FHL1 and RITA1, we used a set of alanine mutants (F261A, V263A, A284V, and Q333A) that we have previously characterized for RAM, FHL1, L3MBTL3, and RITA1 binding to RBPJ (Figure 5G-H and Table 3) 12,13,19,36 . The BTD mutants F261A and A284V, which are more centrally located in the SHARP-BTD interface, have a stronger effect, significantly reducing binding by ~45 fold and ~50 fold, respectively (Figure 5G-H and Table 3).…”